Eli Lilly has invested heavily into obesity, dominating the landscape—alongside semaglutide maker Novo Nordisk—with its ...

One of the highlights of Eli Lilly's ... up by the drugmaker. Lilly's head of diabetes, Mike Mason, said on the company's results call that the rollout of Mounjaro (tirzepatide) was "really ...

That’s how much Eli Lilly’s revenue grew in 2024 ... the revision to lower-than-expected sales of tirzepatide, marketed as Mounjaro for type 2 diabetes and Zepbound for obesity.

Although Mounjaro and Zepbound have been headlining Lilly’s financial reports in recent years, the company’s roster of ...

Eli Lilly and Company's impressive Q4 earnings driven by tirzepatide's success, diverse portfolio, and promising pipeline.

Eli Lilly (NYSE:LLY) reported strong Q4 2024 ... Sales of GLP1 therapy tirzepatide marketed as Mounjaro for diabetes and Zepbound for weight loss reached $5.4 billion reflecting 128% year-over ...

Meanwhile, tirzepatide – the active ingredient in Eli Lilly's weight loss shot Zepbound and diabetes drug Mounjaro –mimics two hunger-regulating hormones, GLP-1 and GIP. Novo Nordisk's weight ...

Demand in the U.S. has far outpaced supply for Eli Lilly’s incretin drugs, such as Zepbound and Mounjaro, over the last year. Eli Lilly on Thursday reported mixed results for the fourth quarter ...